Alivus Life Sciences Ltd

543322

Equity

ISIN INE03Q201024 / Valor 112824626

Bombay Stock Exchange Ltd. (Mumbai) (2026-06-25)

INR 1,106.75-0.84%

Alivus Life Sciences Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Incorporated on 23 June 2011 as Zorg Laboratories Private Limited, acquired by Glenmark Pharmaceuticals in 2018, and renamed Glenmark Life Sciences Limited upon listing, the company was again renamed Alivus Life Sciences Limited in December 2024 following Nirma Limited's acquisition of a majority stake from Glenmark. Headquartered in Mumbai and a subsidiary of Nirma Limited, the company develops, manufactures and markets non-commoditised APIs (active pharmaceutical ingredients) for chronic therapeutic areas including cardiovascular, CNS, diabetes, oncology, GI, pain, urology and anti-infectives. Key APIs include olmesartan, telmisartan, rosuvastatin, sitagliptin and solifenacin. It also provides CDMO services to multinational and specialty pharma companies and exports to Europe, North America, Japan and Latin America.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

9.44%1Y

97.5%3Y

%5Y

Performance

27.8%1Y

35.4%3Y

32.2%5Y

Volatility